Febrile Neutropenia Market Poised for Steady Growth as Biosimilars Reshape Competitive Landscape Through 2036 – DelveInsight
The Febrile Neutropenia market is expected to experience continued expansion during the forecast period, driven by rising cancer incidence and chemotherapy treatment volumes, increasing awareness of neutropenia risks, and the development of outpatient cancer care. The entry and expansion of low-cost biosimilars